Acute myeloid leukemia (AML), the most common form of acute leukemia in adults, is associated with poor outcomes, with only a minority of patients achieving remission with standard chemotherapy. In 2017, four new therapies received approval for AML—the first new therapies in 45 years. Another therapy was approved in July 2018. These agents offer the opportunity for individualization of therapy and improved outcomes. This activity focuses on factors to consider when selecting treatment regimens for AML, appropriate use and efficacy of the new agents, and the identification and management of associated toxicities.
eNewsletter with interactive benchmarking
After completing this activity, participants should be better able to:
- Identify the most common genetic mutations associated with AML and their implications for prognosis and treatment options
- Discuss clinical trial evidence of the safety and efficacy of available and emerging therapies for the treatment of AML
- Address challenges to patient quality of life by incorporating effective treatment, with a focus on managing side effects
Oncology nurse practitioners, physician assistants, and nurses
In support of improving patient care, Continuing Education Alliance is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Nursing contact hours: 1.00, which includes 1.00 hours of pharmacology credit
Nurse planner: Beth Eaby-Sandy, MSN, CRNP, OCN, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania
This program has been reviewed and is approved for a maximum of 1.0 AAPA Category 1 CME credits by the AAPA Review Panel. Approval is valid for one year from the issue date of August 15, 2018. Participants may submit the post-test at any time during that period.
This program was planned in accordance with AAPA CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.
This program was cosupported by educational grants from Astellas and Pfizer; Bristol-Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc; Lilly USA, LLC; Merck & Co., Inc.; Sanofi Genzyme; and Taiho Oncology, Inc. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
This activity is supported by an educational grant from Celgene Corporation and Daiichi Sankyo, Inc.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Continuing Education Alliance, Practicing Clinicians Exchange, the AAPA, or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Continuing Education Alliance are required to disclose to the audience any significant support or substantial relationships with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and planning committee have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr Sweet has no relevant financial relationships to disclose.
The Planning Committee for this activity included Ruth Cohen, Warren Beckman, Craig Borders, Leslie Burgess, Kathleen Crowley, Jacqueline Egan, Margaret Inman, Devera Pine, Marie Recine, and Stef Stendardo of Continuing Education Alliance; Lee Schwartzberg, MD, of the University of Tennessee Health Science Center; Beth Eaby-Sandy, MSN, CRNP, OCN, of the University of Pennsylvania; and Jessica Garner, MMS, PA-C, of the University of the Pacific. The members of the Planning Committee have no relevant relationships to disclose, except for: Ms Eaby-Sandy: consultant: AbbVie; speakers bureau: AstraZeneca, Helsinn, Merck, Takeda; Dr Schwartzberg: consultant: Pfizer.
Participants wishing to earn CE/CME credit must:
- Read the eNewsletter in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form online
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 70%.
The estimated time to complete this activity is 1.00 hours.
Release date: August 15, 2018 Expiration date: August 15, 2019
© 2018 Practicing Clinicians Exchange. All Rights Reserved. OPCE92818-7A